Stately Bio Raises $12M in Seed Funding
Summary
Stately Bio, a Palo Alto, CA based startup developing cell therapies using an ML-powered live-cell imaging platform, raised $12m in seed funding. The company intends to use the new funding to scale its platform technology and mature its internal pipeline of stem cell-derived therapeutics. Founded in 2022 by Frank Li, CEO, Stately Bio is a biotechnology company building machine learning for regenerative medicine. The company has developed a computational platform that enables rapid, real-time insights into cell identity, quality, and behavior based on live-cell imaging. For biopharma companies, these real-time insights translate into faster process development cycles and better control over quality and consistency, ensuring each run meets the purity and functionality needed for patients.